Remove Biosimilars Remove Drug Development Remove Immunity Remove Packaging
article thumbnail

September 2023 Newsletter

Safe Biologics

6 “The Biosimilar Red Tape Elimination Act”, which would prevent the HHS Secretary from requiring switching studies in order for a biosimilar to be deemed “interchangeable” Under U.S. However, S.6 In conclusion, weakening the interchangeability standard is an unnecessary and potentially harmful step.